| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Employee Stock Options (Right to Buy) | 89.8K | $8.98M | $100.06 | Feb 15, 2025 | Direct |
| JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Restricted Share Units | 53.5K | $8.68M | $162.16 | May 1, 2024 | Direct |
| JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Common Stock | 15.5K | $2.43M | $156.15 | Feb 18, 2025 | Direct |
| JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Restricted Share Units | 5.54K | $865K | $156.15 | Feb 15, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | Feb 15, 2025 | 2 | $0 | 4 | Feb 19, 2025 | EVP, Innovative Medicine, R&D |
| JNJ | JOHNSON & JOHNSON | Feb 15, 2025 | 3 | -$60.1K | 4 | Feb 18, 2025 | EVP, Innovative Medicine, R&D |
| JNJ | JOHNSON & JOHNSON | May 1, 2024 | 3 | -$1.59M | 4/A | Oct 31, 2024 | EVP, Innovative Medicine, R&D |
| JNJ | JOHNSON & JOHNSON | Feb 15, 2024 | 2 | $0 | 4 | Feb 20, 2024 | EVP, Innovative Medicine, R&D |
| JNJ | JOHNSON & JOHNSON | May 1, 2023 | 1 | $0 | 4 | May 2, 2023 | EVP, Pharmaceuticals R&D |
| JNJ | JOHNSON & JOHNSON | Apr 3, 2023 | 0 | $0 | 3 | Apr 13, 2023 | EVP, Pharmaceuticals R&D |